Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
AstraZeneca
Dow
Mallinckrodt
Express Scripts

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Empagliflozin; Metformin Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01001962 ↗ Double Blind Placebo Study of JARDIANCEĀ® (Empagliflozin) in Prehypertensives Type II Diabetics Unknown status Aristotle University Of Thessaloniki Phase 4 2016-01-01 Objectives: Primary 1. Primary prevention of new onset of hypertension Secondary 1. Reduction of 24h BP in type II diabetics with prehypertension 2. Reduction of non dipping status, day and nighttime BP, morning BP surge in subjects receiving EMPAGLIFLOZIN 3. Reduction in the total cardiovascular risk 4. 3 years morbidity and mortality rates 5. Arterial de-stiffening, reduction in central aortic blood pressure in subjects receiving EMPAGLIFLOZIN
NCT01159600 ↗ Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes Completed Eli Lilly and Company Phase 3 2010-07-01 The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.
NCT01159600 ↗ Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes Completed Boehringer Ingelheim Phase 3 2010-07-01 The objective of the current study is to investigate the efficacy, safety and tolerability of two doses of BI 10773 compared to placebo given for 24 weeks as add-on therapy to metformin or metformin plus sulfonylurea in patients with Typ 2 Diabetes Mellitus with insufficient glycaemic control.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Empagliflozin; Metformin Hydrochloride

Condition Name

Condition Name for Empagliflozin; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 16
Healthy 15
Type 2 Diabetes Mellitus 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Empagliflozin; Metformin Hydrochloride
Intervention Trials
Diabetes Mellitus, Type 2 35
Diabetes Mellitus 34
Non-alcoholic Fatty Liver Disease 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Empagliflozin; Metformin Hydrochloride

Trials by Country

Trials by Country for Empagliflozin; Metformin Hydrochloride
Location Trials
United States 224
Canada 50
Germany 19
Australia 12
Mexico 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Empagliflozin; Metformin Hydrochloride
Location Trials
Texas 14
Florida 12
Georgia 11
California 11
North Carolina 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Empagliflozin; Metformin Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Empagliflozin; Metformin Hydrochloride
Clinical Trial Phase Trials
Phase 4 15
Phase 3 15
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Empagliflozin; Metformin Hydrochloride
Clinical Trial Phase Trials
Completed 36
Recruiting 14
Not yet recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Empagliflozin; Metformin Hydrochloride

Sponsor Name

Sponsor Name for Empagliflozin; Metformin Hydrochloride
Sponsor Trials
Boehringer Ingelheim 26
Eli Lilly and Company 17
Getz Pharma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Empagliflozin; Metformin Hydrochloride
Sponsor Trials
Industry 60
Other 49
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
McKesson
Boehringer Ingelheim
Harvard Business School
Merck
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.